Umbelliferone in Management of Allergic Asthma; A Systematic Review of its Efficacy and Safety

<p>Allergic asthma is a chronic respiratory disorder characterized by airway inflammation, hyperresponsiveness, and structural remodeling triggered by allergen exposure. Conventional therapies, such as corticosteroids and biologics, provide symptomatic relief but often come with limitations, including adverse effects, high costs, and accessibility challenges. Umbelliferone, a naturally occurring coumarin derivative, has emerged as a promising therapeutic option due to its multifaceted pharmacological properties. This review explores the therapeutic potential of Umbelliferone in managing allergic asthma, focusing on its anti-inflammatory, antioxidant, immunomodulatory and bronchodilatoryeffects.Umbelliferone exerts its anti-inflammatory effects by modulating key signaling pathways such as NF-κB, MAPK, and JAK/STAT. These actions reduce the production of proinflammatory cytokines, including IL-4, IL-5, and IL-13, which drive Th2-mediated immune responses in asthma. Additionally, Umbelliferone mitigates airway inflammation by preventing the infiltration of eosinophils and other immune cells into lung tissues.Its potent antioxidant properties address the oxidative stress that exacerbates asthma symptoms and airway damage. By scavenging reactive oxygen species (ROS) and enhancing the activity of antioxidant enzymes like superoxide dismutase (SOD) and glutathione peroxidase (GPx), Umbelliferone protects respiratory tissues from oxidative injury. These actions also prevent the activation of redox-sensitive inflammatory pathways, contributing to improved airway health.In terms of airway remodeling,Umbelliferone inhibits the fibrotic changes and smooth muscle hypertrophy associated with chronic asthma. By targeting TGF-β signaling and matrix metalloproteinase activity, it reduces fibrosis and extracellular matrix deposition, preserving lung function and preventing disease progression. Its bronchodilatory effects further alleviate symptoms by relaxing airway smooth muscles, improving airflow and reducing hyperresponsiveness.Preclinical studies have demonstrated significant reductions in airway inflammation, oxidative stress, and remodeling with Umbelliferone administration in murine models of asthma. Limited clinical trials have also reported improvements in lung function and symptom relief, with minimal side effects and a favorable safety profile. However, challenges remain, including its low bioavailability and the need for large-scale clinical validation. Advanced drug delivery systems, such as nanoparticles and sustained-release formulations could address these limitations and enhance its therapeutic potential.In conclusion, Umbelliferone represents a promising natural therapeutic option for allergic asthma, offering a comprehensive approach to disease management. Its ability to target multiple aspects of asthma pathophysiology positions it as a valuable alternative or adjunct to existing therapies. Further research is essential to establish its clinical efficacy, optimize dosage, and unlock its full potential for widespread application.</p>